Detoxification of the Toxic Sulfur Mustard Simulant by a Supramolecular Antidote in Vitro and in Vivo
Source abstract
Abstract
Although great potential hazards and threats still occur from sulfur mustard, there are no specific medicine or therapy for the intoxication of sulfur mustard. Herein, we have demonstrated a supramolecular approach for the detoxification of the sulfur mustard simulant CEES (4) in vitro and in vivo by carboxylatopillar[5]arene potassium salts (CP[5]AK 1) efficiently based on host–guest interactions. The encapsulation of CEES (4) by the cavity of the pillar[5]arene 2 is driven by C–H···π interactions between CEES (4) and the electron-rich cavity of pillar[5]arene 2, which was investigated by 1H NMR titration, density functional theory studies, and the independent gradient model studies. CEES (4) is degradated to the reactive sulfonium salts quickly in aqueous media, resulting in the alkylation of DNA and proteins. The sulfonium salts can be encapsulated by CP[5]AK 1 efficiently, which accelerates the degradation of the sulfonium salts about 14 times. The cell and animal experiments indicated that the bioactivities of the sulfonium salts are inhibited with the formation of stable host–guest complexes, and CP[5]AK 1 has a good therapeutic effect on the damages caused by CEES (4) at either pre- or post-treatments. Due to the low cytotoxicity and good therapeutic effect, the anionic pillar[5]arenes are expected to be developed as specific antidotes against sulfur mustard (HD).
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Pesticide Exposure and Toxicity · Chemical Reaction Mechanisms · Synthesis and Characterization of Heterocyclic Compounds
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
The Institute for Advanced Studies, Wuhan University, 299 Bayi Road, Wuhan, Hubei 430072, China
Department of Ophthalmology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China
Funding
National Natural Science Foundation of China
References (55)
Show source-provided references
1. 10.2105/ajph.2007.11193010.2105/ajph.2007.111930 ↗
2. 10.1021/cr00016a00310.1021/cr00016a003 ↗
3. 10.1021/cr100193y10.1021/cr100193y ↗
4. 10.1345/aph.1k44510.1345/aph.1k445 ↗
5. 10.1017/s1049023x0000649x10.1017/s1049023x0000649x ↗
6. 10.1002/adma.20190578510.1002/adma.201905785 ↗
7. 10.1016/s0021-9673(98)00338-010.1016/s0021-9673(98)00338-0 ↗
8. 10.1021/ja401845e10.1021/ja401845e ↗
9. 10.1039/b705025a10.1039/b705025a ↗
10. 10.1016/j.ccr.2017.10.01010.1016/j.ccr.2017.10.010 ↗
11. 10.1021/jo901713c10.1021/jo901713c ↗
12. 10.1021/acsnano.5b0566010.1021/acsnano.5b05660 ↗
13. 10.1002/chem.20200366510.1002/chem.202003665 ↗
14. 10.1021/ja901872y10.1021/ja901872y ↗
15. 10.1039/c9cc04928b10.1039/c9cc04928b ↗
16. 10.1016/j.cbi.2013.09.01510.1016/j.cbi.2013.09.015 ↗
17. 10.1016/0190-9622(95)91457-910.1016/0190-9622(95)91457-9 ↗
18. 10.1039/c2ob26482j10.1039/c2ob26482j ↗
19. 10.1007/bf0188739410.1007/bf01887394 ↗
20. 10.1016/j.tox.2005.06.01410.1016/j.tox.2005.06.014 ↗
21. 10.1016/0165-6147(91)90534-y10.1016/0165-6147(91)90534-y ↗
22. 10.1097/01.jom.0000094993.20914.d110.1097/01.jom.0000094993.20914.d1 ↗
23. 10.2174/138161282266616102115012510.2174/1381612822666161021150125 ↗
24. 10.1039/b615227a10.1039/b615227a ↗
25. 10.1111/j.1472-8206.2005.00325.x10.1111/j.1472-8206.2005.00325.x ↗
26. Dacre J. C. · Pharmacol. Rev. · 1996 · 48 · 289
27. 10.1080/10408444.2020.183706910.1080/10408444.2020.1837069 ↗
28. 10.1111/nyas.1433610.1111/nyas.14336 ↗
29. 10.3109/1040844910908988010.3109/10408449109089880 ↗
30. 10.1016/j.tox.2014.09.00510.1016/j.tox.2014.09.005 ↗
31. 10.1039/d0ob01167c10.1039/d0ob01167c ↗
32. 10.1038/sj.emboj.760062010.1038/sj.emboj.7600620 ↗
33. 10.1021/acs.jmedchem.0c0120210.1021/acs.jmedchem.0c01202 ↗
34. 10.1111/bcpt.1239810.1111/bcpt.12398 ↗
35. 10.7150/thno.3165310.7150/thno.31653 ↗
36. 10.1213/01.ane.0000244594.63318.fc10.1213/01.ane.0000244594.63318.fc ↗
37. 10.1002/anie.20120603110.1002/anie.201206031 ↗
38. 10.1021/ja309990510.1021/ja3099905 ↗
39. 10.1021/jf104571q10.1021/jf104571q ↗
40. 10.1021/jm900811z10.1021/jm900811z ↗
41. 10.1002/anie.20160688110.1002/anie.201606881 ↗
42. 10.1021/ja408585j10.1021/ja408585j ↗
43. 10.1021/acsnano.0c0111910.1021/acsnano.0c01119 ↗
44. 10.1039/d1sc00426c10.1039/d1sc00426c ↗
45. 10.1021/acsami.1c0579810.1021/acsami.1c05798 ↗
46. 10.1016/j.isci.2020.10144310.1016/j.isci.2020.101443 ↗
47. 10.1021/acsomega.8b0209110.1021/acsomega.8b02091 ↗
48. Frisch, M. J.; Trucks, G. W.; Schlegel, H. B.; Scuseria, G. E.; Robb, M. A.; Cheeseman, J. R.; Scalmani, G.; Barone, V.; Petersson, G. A.; Nakatsuji, H.; Li, X.; Caricato, M.; Marenich, A. V.; Bloino, J.; Janesko, B. G.; Gomperts, R.; Mennucci, B.; Hratchian, H. P.; Ortiz, J. V.; Izmaylov, A. F.; Sonnenberg, J. L.; Ding, F.; Lipparini, F.; Egidi, F.; Goings, J.; Peng, B.; Petrone, A.; Henderson, T.; Ranasinghe, D.; Zakrzewski, V. G.; Gao, J.; Rega, N.; Zheng, G.; Liang, W.; Hada, M.; Ehara, M.; Toyota, K.; Fukuda, R.; Hasegawa, J.; Ishida, M.; Nakajima, T.; Honda, Y.; Kitao, O.; Nakai, H.; Vreven, T.; Throssell, K.; Montgomery, J. A., Jr.; Peralta, J. E.; Ogliaro, F.; Bearpark, M. J.; Heyd, J. J.; Brothers, E. N.; Kudin, K. N.; Staroverov, V. N.; Keith, T. A.; Kobayashi, R.; Normand, J.; Raghavachari, K.; Rendell, A. P.; Burant, J. C.; Iyengar, S. S.; Tomasi, J.; Cossi, M.; Millam, J. M.; Klene, M.; Adamo, C.; Cammi, R.; Ochterski, J. W.; Martin, R. L.; Morokuma, K.; Farkas, O.; Foresman, J. B.; Fox, D. J. Gaussian 09, Rev. A.02; Wallingford, CT, 2013.
49. 10.1002/jcc.2288510.1002/jcc.22885 ↗
50. 10.1021/ja100936w10.1021/ja100936w ↗
51. 10.1021/jo400392b10.1021/jo400392b ↗
52. 10.1080/10426507.2013.82072810.1080/10426507.2013.820728 ↗
53. 10.1021/jo061994010.1021/jo0619940 ↗
54. 10.1016/j.yexmp.2019.10427510.1016/j.yexmp.2019.104275 ↗
55. 10.1136/bjophthalmol-2015-30741510.1136/bjophthalmol-2015-307415 ↗